Jasper Therapeutics, Inc. has reached a significant milestone by completing enrollment for the IgA nephropathy cohort in its Phase 2 basket study evaluating vensobafusp alfa (KP104). This development is crucial for the company as it seeks to advance its innovative therapies targeting immune-mediated diseases.
The completion of enrollment signifies Jasper's commitment to addressing unmet medical needs in kidney diseases. The company expects to report initial interim data from the IgAN basket study by the end of 2026, which could provide valuable insights into the efficacy of vensobafusp alfa.
Founded in Redwood City, California, Jasper Therapeutics operates under the SIC code 2836, which pertains to biological products (no diagnostic substances). The company is publicly traded on the Nasdaq under the ticker symbol JSPR. Jasper's recent filings include a variety of reports, with the most recent being the 8-K filed on October 15, 2026, detailing the completion of enrollment.
In its SEC filing, Jasper reported, "On October 15, 2026, Jasper Therapeutics, Inc. issued a press release announcing that it completed enrollment of the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104)." The filing also included an exhibit with a press release that elaborated on the study's progress.
The impact of this development may extend to patients suffering from IgAN, a condition characterized by kidney damage that can lead to end-stage kidney disease. The completion of enrollment in this study reflects the high unmet need in this area and the potential for vensobafusp alfa to offer new treatment options.
Looking ahead, Jasper Therapeutics is not only focused on the IgAN cohort but is also expanding its study to include an additional cohort evaluating vensobafusp alfa in focal segmental glomerulosclerosis (FSGS). The first patients in this new cohort are anticipated to be dosed in the first quarter of 2027. The filing does not specify any further actions or upcoming votes related to this development.